Innovations in Action: Emerging Clinical Trials in Head and Neck Cancers

There are many ongoing clinical trials in head and neck squamous cell carcinoma (HNSCC) that offer potential therapeutic benefits to HNSCC patients. This session summarizes those trials and their results. Failure to stay informed of these clinical advances leads to lower quality of cancer care by practicing oncologists.

Oncologists who treat head and neck squamous cell carcinoma (HNSCC) must understand ongoing clinical trials. This session provides attendees the opportunity to gain exposure to the latest clinical research in HNSCC.

This session includes three topics: novel systemic therapy, immunotherapy, and therapy de-escalation. The speakers summarize the state of the field, preliminary results of ongoing clinical trials in these three areas, and clinical trial design for planned trials. The speakers also provide scientific rationale for the emerging trials.

 

Target Audience

This meeting was designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Be aware of the novel systematic strategies for head and neck cancers.
  • Understand that innovative immunotherapy approaches are being tested in head and neck cancers.
  • Recognize that de-escalation of therapy for head and neck cancers may lead to lower long term toxicity.

 

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
02/09/2026
Course expires: 
03/01/2028
Cost:
$0.00
Rating: 
0

All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.